Neurotech Players Take Part in 2025 MedTech Conference
The 2025 MedTech Conference, organized , brought medical device industry professionals from around the world to San Diego, CA earlier this month. The four-day event featured a variety of sessions devoted to key topics such as reimbursement, international markets, investment, and patient engagement [see article, p3]. One of the most valuable features of this year’s conference was a series of investor forums organized .
AI-Assisted Diagnostics May Drive Future BioElectRx Products
This newsletter often covers the development of diagnostic devices that help identify disease severity and select suitable candidates for bioelectronic medicine therapies. A case in point is the use of cervical VNS for treating heart failure with reduced ejection fraction. Several clinical trials for HFrEF led , Boston Scientific, and LivaNova failed their primary endpoints, even though they were successful for a subset of patients.
Neurotech Teams Seek to Tackle Common Addiction Disorders
Neurotech researchers and commercial firms have devised therapeutic approaches to treating a number of psychiatric disorders, such as major depression, OCD, and anxiety. More recently, some research teams have set their site on treating addiction, and one firm, Spark Biomedical, has obtained FDA clearance for its noninvasive Sparrow device to treat opioid use disorder. But a more challenging and ubiquitous form of addiction involves substances that are legal and commercially available, namely tobacco and alcohol.
Testing Our Limits
Anyone who follows aviation, as this editor does, is eager to learn about the features and capabilities of new aircraft when they get introduced, particularly if there is something groundbreaking about the design. But most pilots would not be so eager to get behind the controls and fly one of those new planes before has undergone testing. That is the role of a test pilot. It doesn’t happen often, b…
Cleveland Neurodesign Workshop Marks Student Milestone
The Cleveland Neurodesign Entrepreneurs Workshop, a novel program dedicated to cultivating entrepreneurship in neurotechnology, reached a major milestone earlier this month when it welcomed its 200th student. Modeled on the Stanford Biodesign framework but tailored to the unique challenges of neurotech commercialization, CNEW continues to serve as a launchpad for the next generation of innovators.
Medtronic Tibial Stim Approval to Impact OAB Market
According to our 2024 Market Report on Bioelectronic Medicine, OAB is the leading segment in the bioelectronic medicine market and is poised for continued growth in coming years due to an aging population, chronic stress, and growing patient awareness of neuromodulation therapies. In the OAB market, implantable SNS devices hold the lion’s share, while wearable devices for percutaneous and transcutaneous tibial nerve stimulation remain on the margins, as we reported in our December 2024 issue.
Entrepreneur Presenters and Panelists Added to Neurotech Leaders Forum Agenda
Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several panelists and presenters have been added to the agenda for the 25th annual Neurotech Leaders Forum, which take place November 5-6, 2025 in San Francisco. New speakers include Murthy Simhabhatla, CEO of SetPoint Medical, Ryan Field, CEO of Kernel, Andreas Forland, CEO of Cognixion, and Oliver Armitage, newly appointed vice president of Axoft.
Magnetoelectric Network May Control Multiple Targets
Since the early days of the neurotechnology industry, neural engineers have sought to devise networks of implantable neurostimulators that can deliver stimulation to different anatomical targets and communicate with other devices on the network. Twenty years ago, researchers at the Alfred Mann Foundation presented the concept of a networked neuroprosthesis consisting of multiple injectable BION stimulators.
Subsense Looks to Nanoparticles as Unique BCI Approach
Subsense, Inc., the Palo Alto, CA manufacturer of brain neuromodulation systems, is not the only startup to target the market for brain-computer interfaces. But the company’s novel nanoparticle-based noninvasive technology stands to set the firm apart from the myriad others entering this space. The company emerged from stealth mode in February of this year, and earlier this month, hosted an open house at its California headquarters.
Glass Houses of Cards
By now, most professionals in the neuromodulation industry have become aware of some of the negative news reports and journal articles calling into question the value of spinal cord stimulation for treating back pain. The SCS industry has fought back on a number of fronts and continues to offer product enhancements and sponsor clinical trials that can produce the scientific evidence necessary to convince patients, payers, and regulators that the therapy is effective and appropriate.